MX2008010896A - Metodo para detectar o diagnosticar una enfermedad o condicion neurodegenerativa. - Google Patents

Metodo para detectar o diagnosticar una enfermedad o condicion neurodegenerativa.

Info

Publication number
MX2008010896A
MX2008010896A MX2008010896A MX2008010896A MX2008010896A MX 2008010896 A MX2008010896 A MX 2008010896A MX 2008010896 A MX2008010896 A MX 2008010896A MX 2008010896 A MX2008010896 A MX 2008010896A MX 2008010896 A MX2008010896 A MX 2008010896A
Authority
MX
Mexico
Prior art keywords
sample
level
condition
neurodegenerative disease
autoantibody
Prior art date
Application number
MX2008010896A
Other languages
English (en)
Inventor
John A Mcintyre
Original Assignee
John A Mcintyre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John A Mcintyre filed Critical John A Mcintyre
Publication of MX2008010896A publication Critical patent/MX2008010896A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Una enfermedad o condición neurodegenerativa es diagnosticada al obtener una muestra de fluido cerebral espinal y someter a ensayo la muestra para detectar la presencia de al menos un autoanticuerpo antifosfolipídico o anticuerpos nitrosilados en la muestra, un nivel elevado de los cuales se correlaciona con una enfermedad o condición neurodegenerativa; de manera alternativa, al someter a ensayo una primera muestra para determinar un nivel de por lo menos un autoanticuerpo que tiene una especificidad seleccionada, tratar una segunda muestra con un agente oxidante, someter a ensayo la segunda muestra oxidada para determinar un nivel del autoanticuerpo o autoanticuerpos que tienen la especificidad seleccionada, y comparar el nivel del autoanticuerpo o autoacticuerpos en la primer muestra con aquel en la segunda muestra oxidada, una falta de incremento en el nivel del autoanticuerpo o autoanticuerpos en la segunda muestra oxidada en comparación con el nivel en la primera muestra se correlaciona con una enfermedad o condición neurodegenerativa.
MX2008010896A 2006-02-23 2007-01-22 Metodo para detectar o diagnosticar una enfermedad o condicion neurodegenerativa. MX2008010896A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/359,489 US7892751B2 (en) 2003-06-09 2006-02-23 Method of detecting or diagnosing of a neurodegenerative disease or condition
PCT/US2007/001582 WO2007106224A2 (en) 2006-02-23 2007-01-22 Method of detecting or diagnosing of a neurodegenerative disease or condition

Publications (1)

Publication Number Publication Date
MX2008010896A true MX2008010896A (es) 2008-11-25

Family

ID=38509957

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010896A MX2008010896A (es) 2006-02-23 2007-01-22 Metodo para detectar o diagnosticar una enfermedad o condicion neurodegenerativa.

Country Status (9)

Country Link
US (1) US7892751B2 (es)
EP (1) EP1989551B1 (es)
JP (1) JP4880001B2 (es)
AT (1) ATE550658T1 (es)
AU (1) AU2007225434B2 (es)
BR (1) BRPI0708138A2 (es)
CA (1) CA2642869C (es)
MX (1) MX2008010896A (es)
WO (1) WO2007106224A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2010003602A1 (en) * 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for alzheimer's disease
AU2009289520B2 (en) * 2008-09-04 2013-09-12 Redox-Reactive Reagents, Llc Biomarkers, kits, and method for diagnosing, monitoring, and/or staging Alzheimer's disease
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
US20120107841A1 (en) * 2010-07-19 2012-05-03 Mcintyre John A Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3086120B1 (en) * 2015-04-22 2019-07-31 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a novel autoimmune disease
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703001A (en) * 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4950612A (en) 1987-12-16 1990-08-21 Microgenics Corporation Peroxy acid pretreatment in vitamin B12 assay
US5061790A (en) * 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
AU703814B2 (en) 1995-12-04 1999-04-01 Wyeth Antioxidant
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR2822238B1 (fr) * 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
JP4662557B2 (ja) * 2003-06-09 2011-03-30 レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー 酸化還元反応による血漿タンパク質の結合特異性の改変方法
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition

Also Published As

Publication number Publication date
WO2007106224A3 (en) 2008-01-31
BRPI0708138A2 (pt) 2011-05-17
JP2009527762A (ja) 2009-07-30
AU2007225434A1 (en) 2007-09-20
EP1989551A2 (en) 2008-11-12
CA2642869A1 (en) 2007-09-20
JP4880001B2 (ja) 2012-02-22
CA2642869C (en) 2017-04-11
US20060141541A1 (en) 2006-06-29
EP1989551A4 (en) 2010-01-06
AU2007225434B2 (en) 2011-05-26
WO2007106224B1 (en) 2008-03-20
EP1989551B1 (en) 2012-03-21
ATE550658T1 (de) 2012-04-15
US7892751B2 (en) 2011-02-22
WO2007106224A2 (en) 2007-09-20
AU2007225434A8 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
MX2008010896A (es) Metodo para detectar o diagnosticar una enfermedad o condicion neurodegenerativa.
WO2010057184A3 (en) Methods for detection of acute kidney injury in humans
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
NZ705411A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP4235181A3 (en) Biomarker detection process and assay of neurological condition
NZ601575A (en) Methods and compositions for diagnosis and prognosis of renal injury and failure
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CO6741144A2 (es) Indicador vaginal para detectar biomarcadores de una buena salud
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2767833A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
GB2467704A (en) Methods of monitoring conditions by sequence analysis
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011021041A3 (en) Survival prognostic assay
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CO6311041A2 (es) Un metodo para determinar y monitorear un cancer ginecologico que comprende la determinacion de niveles de biomarcadores en una muestra biologica
NZ598741A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample
NZ605561A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2530574T3 (es) Biomarcadores asociados a la nefropatía
GB0723882D0 (en) Methods for the detection of a threatened miscarriage

Legal Events

Date Code Title Description
FG Grant or registration